Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.31 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.31 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.31 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1173646 | 0.84 | — | — | |
| SCHEMBL1173292 | 0.67 | KMT2A (0.36) | PABPC1LMNATSHR | |
| SCHEMBL9505075 | 0.59 | PABPC1 (0.41) | CYP1A2PABPC1LMNATSHR | |
| SCHEMBL20841978 | 0.59 | CYP1A2 (0.57) | CYP1A2LMNAGAATSHRCES2 | |
| SCHEMBL5972567 | 0.59 | CYP1A2 (0.57) | CYP1A2LMNAGAATSHRCES2 | |
| SCHEMBL15720578 | 0.57 | TSHR (0.43) | CYP1A2PABPC1LMNAGAAHPGD | |
| Biphenyl SCHEMBL27859632 | 0.57 | CYP1A2 (0.93) | CYP1A2LMNAGAATSHRCES2 | |
| SCHEMBL337270 | 0.57 | LMNA (0.57) | CYP1A2LMNAHPGDTSHRCES2 | |
| Hydrochloric Acid SCHEMBL17259945 | 0.56 | TSHR (0.41) | CYP1A2PABPC1LMNAGAAHPGD | |
| Hydrochloric Acid SCHEMBL17259914 | 0.56 | TSHR (0.41) | CYP1A2PABPC1LMNAGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436173-B2 | Boron compounds, their production processes, and functional electronic devices using same | KYOTO UNIVERSITY (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20110046372-A1 | NOVEL BORON COMPOUNDS, THEIR PRODUCTION PROCESSES, AND FUNCTIONAL ELECTRONIC DEVICES USING SAME | Kyoto University and Nippon Shokubai Co., LTD. | 2011-02-24 | — | — | US | disclosed |
| EP-2233490-A1 | NOVEL BORON COMPOUND, METHOD FOR PRODUCING THE SAME, AND FUNCTIONAL ELECTRONIC DEVICE USING THE SAME | Kyoto University (JP) | 2010-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046372-A1 | NOVEL BORON COMPOUNDS, THEIR PRODUCTION PROCESSES, AND FUNCTIONAL ELECTRONIC DEVICES USING SAME | ETFB, SLC40A1, SLC19A1 | CYP1A2 3205/4885PABPC1 1876/4885LMNA 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.